First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.
Rodon J, Prenen H, Sacher A, Villalona-Calero M, Penel N, El Helali A, Rottey S, Yamamoto N, Ghiringhelli F, Goebeler ME, Doi T, Postel-Vinay S, Lin CC, Liu C, Chuang CH, Keyvanjah K, Eggert T, O'Neil BH.
Rodon J, et al. Among authors: lin cc.
Ann Oncol. 2024 Dec;35(12):1138-1147. doi: 10.1016/j.annonc.2024.08.2339. Epub 2024 Sep 16.
Ann Oncol. 2024.
PMID: 39293516
Clinical Trial.